Akums Drugs and Pharmaceuticals Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Attractively valued vs sector (P/E 39.5x vs industry 54.7x)
- Virtually debt-free
Concerns
- Trading near 52-week high (₹797)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,899 | ₹4.6L Cr | 36.1 | 5.46 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,100 | ₹2.4L Cr | 81.1 | 14.42 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,857 | ₹1.8L Cr | 82.8 | 19.58 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,650 | ₹1.2L Cr | 59.1 | 13.13 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,385 | ₹1.1L Cr | 31.3 | 3.25 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,120 | ₹1.1L Cr | 23 | 4.16 | 21.2 | 21.1 | 0.38 |
| LAURUSLABS Laurus Labs Limited | ₹1,840 | ₹99K Cr | 90.9 | 18.74 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
AKUMS · as of Jun 2026
| Category | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% |
| FII | 5.77% | 4.24% | 2.27% | 1.14% | 1.38% | 1.91% |
| DII | 7.39% | 8.85% | 9.28% | 14.41% | 14.36% | 13.44% |
| Public | 8.84% | 8.92% | 10.46% | 6.45% | 6.29% | 6.67% |
| Others | 2.73% | 2.73% | 2.73% | 2.73% | 2.73% | 2.73% |
Corporate Events
Intimation of Board Meeting
Dividend - Re 1 Per Share/Special Dividend - Rs 2 Per Share
Latest News
All newsAkums receives ESG rating update
*Akums receives ESG rating update.* The company has disclosed its latest ESG rating in a regulatory filing. This non-financial assessment reflects sustainability and governance practices. **No immediate financial impact** is expected. 📊 *STOCKS:* $AKUMS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ESG
Akums to host investor meet on August 25, 2026
*Akums to host investor meet on August 25, 2026.* The company announced the schedule for its analyst and institutional investor meet. **No financial updates or major announcements** were disclosed in the filing. It is a routine corporate communication ahead of the event. 📊 *STOCKS:* $AKUMS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet
Akums to host analyst and investor meet.
*Akums to host analyst and investor meet.* The event is scheduled to provide updates to institutional investors and analysts. No financial announcements or major developments were indicated. It’s a routine engagement to maintain investor relations. 📊 *STOCKS:* $AKUMS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet
Akums hosts investor call; no major announcements.
*Akums hosts investor call; no major announcements.* The company shared updates during its analyst and institutional investor meet, though no significant financial or operational disclosures were made. Transcript available via NSE corporate filing. Business outlook remains stable with no changes to guidance. 📊 *STOCKS:* $AKUMS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorCall
Akums publishes mandatory newspaper notice
*Akums publishes mandatory newspaper notice.* This is a routine corporate disclosure as required by regulatory norms. No financial or operational updates were provided. Such filings are standard and do not impact business operations. 📊 *STOCKS:* $AKUMS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CorporateFiling
Akums acquires Oriflame India's unit for ₹56 crore
*Akums acquires Oriflame India's manufacturing unit for ₹56 crore.* This marks a strategic diversification beyond pharmaceuticals into FMCG manufacturing. The move expands Akums’ production capabilities and client base in contract manufacturing. **₹56 crore** investment underscores growing vertical integration ambitions. 📊 *STOCKS:* $AKUMS | 🏢 *SECTOR:* Corporate | #MEDIUMIMPACT #Acquisition
Akums to hold 22nd Annual General Meeting
*Akums to hold 22nd Annual General Meeting* as per a newspaper publication notice. The AGM is a routine annual event for shareholders. No major corporate announcements were disclosed in the filing. Details on dividends or key resolutions are awaited. 📊 *STOCKS:* AKUMS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AGM
Akums shares to see e-voting updates for FY2025-26
*Akums shares to see e-voting updates for FY2025-26*. Akums Drugs and Pharmaceuticals has issued a notice and integrated annual report for FY2025-26 to shareholders without registered email IDs. The move ensures compliance with SEBI’s e-voting and investor communication norms. Physical dispatch may lead to minor administrative costs. 📊 *STOCKS:* AKUMS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AnnualReport
Akums announces 22nd AGM and final dividend details.
*Akums announces 22nd AGM and final dividend details.* The company has released an advertisement informing shareholders about the date and logistics of its 22nd Annual General Meeting. It also confirmed the disbursement of **final and special dividends**, details of which are outlined in the filing. Investors should watch for record and payment dates. 📊 *STOCKS:* AKUMS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Dividend
Akums to host analyst and investor meet
*Akums to host analyst and investor meet* to discuss business updates and strategy. The company has scheduled an investor/analyst meeting, as per a regulatory filing. Such events often provide clarity on guidance and operational performance. No financial figures or major announcements were disclosed. 📊 *STOCKS:* AKUMS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma
Financials
Quarterly Results
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1.2K Cr 0.2% | ₹1.2K Cr 13.9% | ₹1.0K Cr 0.6% | ₹1.0K Cr 3.0% | ₹1.1K Cr 4.6% | ₹1.0K Cr 2.2% | ₹1.0K Cr 1.4% | ₹1.0K Cr |
| Op. Profit | ₹152 Cr 3.4% | ₹147 Cr 56.4% | ₹94 Cr 27.1% | ₹129 Cr 37.2% | ₹94 Cr 22.3% | ₹121 Cr 0.0% | ₹121 Cr 5.5% | ₹128 Cr |
| OPM | 13.0% 0.0% | 13.0% 44.4% | 9.0% 30.8% | 13.0% 44.4% | 9.0% 25.0% | 12.0% 0.0% | 12.0% 7.7% | 13.0% |
| Net Profit | ₹81 Cr 19.1% | ₹68 Cr 58.1% | ₹43 Cr 33.8% | ₹65 Cr 56.7% | ₹150 Cr 127.3% | ₹66 Cr 1.5% | ₹67 Cr 9.8% | ₹61 Cr |
| EPS (₹) | 5.38 27.8% | 4.21 62.5% | 2.59 35.7% | 4.03 57.0% | 9.38 126.6% | 4.14 0.0% | 4.14 1.5% | 4.08 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2016 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹4.4K Cr 5.9% | ₹4.1K Cr 1.4% | ₹4.2K Cr 14.3% | ₹3.7K Cr 0.5% | ₹3.7K Cr 34.9% | ₹2.7K Cr 12.8% | ₹2.4K Cr 46.2% | ₹1.7K Cr 12.8% | ₹1.5K Cr |
| Expenses | ₹3.8K Cr 5.0% | ₹3.7K Cr 9.9% | ₹4.1K Cr 20.6% | ₹3.4K Cr 10.6% | ₹3.8K Cr 51.3% | ₹2.5K Cr 10.9% | ₹2.2K Cr 48.6% | ₹1.5K Cr 12.5% | ₹1.3K Cr |
| Op. Profit | ₹522 Cr 12.3% | ₹465 Cr 278.0% | ₹123 Cr 58.2% | ₹294 Cr 430.3% | ₹-89 Cr 137.4% | ₹238 Cr 36.8% | ₹174 Cr 20.8% | ₹144 Cr 16.1% | ₹124 Cr |
| OPM | 12.0% 9.1% | 11.0% 266.7% | 3.0% 62.5% | 8.0% 433.3% | -2.4% 126.7% | 9.0% 28.6% | 7.0% 22.2% | 9.0% 12.5% | 8.0% |
| Other Income | ₹108 Cr 56.5% | ₹69 Cr 762.5% | ₹8 Cr 46.7% | ₹15 Cr 114.3% | ₹7 Cr 36.4% | ₹11 Cr 57.7% | ₹26 Cr 333.3% | ₹6 Cr 0.0% | ₹6 Cr |
| Interest | ₹94 Cr 168.6% | ₹35 Cr 31.4% | ₹51 Cr 10.9% | ₹46 Cr 170.6% | ₹17 Cr 142.9% | ₹7 Cr 65.0% | ₹20 Cr 9.1% | ₹22 Cr 4.3% | ₹23 Cr |
| Depreciation | ₹155 Cr 1.3% | ₹153 Cr 21.4% | ₹126 Cr 11.5% | ₹113 Cr 18.9% | ₹95 Cr 35.7% | ₹70 Cr 4.5% | ₹67 Cr 76.3% | ₹38 Cr 22.6% | ₹31 Cr |
| PBT | ₹382 Cr 10.7% | ₹345 Cr 866.7% | ₹-45 Cr 130.0% | ₹150 Cr 177.7% | ₹-193 Cr 212.2% | ₹172 Cr 50.9% | ₹114 Cr 28.1% | ₹89 Cr 15.6% | ₹77 Cr |
| Tax % | 33.0% | 0.0% 100.0% | -102.0% 391.4% | 35.0% 16.7% | 30.0% 7.1% | 28.0% 54.8% | 62.0% 24.0% | 50.0% 2.0% | 51.0% |
| Net Profit | ₹256 Cr 25.6% | ₹344 Cr 34300.0% | ₹1 Cr 99.0% | ₹98 Cr 139.0% | ₹-251 Cr 304.1% | ₹123 Cr 179.5% | ₹44 Cr 27.9% | ₹61 Cr 41.9% | ₹43 Cr |
| EPS (₹) | 16.21 24.6% | 21.49 7775.0% | -0.28 104.2% | 6.63 118.8% | -35.3 103.7% | 943.49 181.1% | 335.61 35.9% | 523.23 42.7% | 366.55 |
| Div Payout | 18.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2016 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|
Liabilities | |||||||||
| Equity Capital | ₹31 Cr 0.0% | ₹31 Cr 6.9% | ₹29 Cr 0.0% | ₹29 Cr 107.1% | ₹14 Cr 1300.0% | ₹1 Cr 0.0% | ₹1 Cr 0.0% | ₹1 Cr 0.0% | ₹1 Cr |
| Reserves | ₹3.3K Cr 8.9% | ₹3.0K Cr 342.9% | ₹681 Cr 1.2% | ₹689 Cr 13.3% | ₹608 Cr 31.2% | ₹884 Cr 22.6% | ₹721 Cr 14.8% | ₹628 Cr 27.4% | ₹493 Cr |
| Borrowings | ₹157 Cr 78.4% | ₹88 Cr 84.4% | ₹565 Cr 8.7% | ₹619 Cr 56.7% | ₹395 Cr 203.8% | ₹130 Cr 25.7% | ₹175 Cr 17.8% | ₹213 Cr 16.5% | ₹255 Cr |
| Other Liabilities | ₹2.0K Cr 104.0% | ₹960 Cr 56.9% | ₹2.2K Cr 17.0% | ₹1.9K Cr 6.3% | ₹2.0K Cr 78.8% | ₹1.1K Cr 0.3% | ₹1.1K Cr 258.5% | ₹318 Cr 8.5% | ₹293 Cr |
| Total Liabilities | ₹5.4K Cr 32.6% | ₹4.1K Cr 16.9% | ₹3.5K Cr 8.1% | ₹3.2K Cr 6.3% | ₹3.0K Cr 41.7% | ₹2.2K Cr 5.6% | ₹2.0K Cr 75.5% | ₹1.2K Cr 11.4% | ₹1.0K Cr |
Assets | |||||||||
| Fixed Assets | ₹1.5K Cr 4.2% | ₹1.4K Cr 17.3% | ₹1.2K Cr 8.6% | ₹1.1K Cr 7.4% | ₹1.0K Cr 12.9% | ₹904 Cr 40.2% | ₹645 Cr 28.7% | ₹501 Cr 12.8% | ₹444 Cr |
| CWIP | ₹177 Cr 8.6% | ₹163 Cr 16.4% | ₹195 Cr 89.3% | ₹103 Cr 232.3% | ₹31 Cr 82.4% | ₹17 Cr 70.2% | ₹57 Cr 418.2% | ₹11 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr 100.0% | ₹20 Cr 233.3% | ₹6 Cr 66.7% | ₹18 Cr | ₹0 Cr |
| Other Assets | ₹3.8K Cr 49.7% | ₹2.5K Cr 19.7% | ₹2.1K Cr 3.8% | ₹2.0K Cr 2.2% | ₹2.0K Cr 64.9% | ₹1.2K Cr 8.8% | ₹1.3K Cr 110.3% | ₹632 Cr 5.7% | ₹598 Cr |
| Total Assets | ₹5.4K Cr 32.6% | ₹4.1K Cr 16.9% | ₹3.5K Cr 8.1% | ₹3.2K Cr 6.3% | ₹3.0K Cr 41.7% | ₹2.2K Cr 5.6% | ₹2.0K Cr 75.5% | ₹1.2K Cr 11.4% | ₹1.0K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2016 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹1.2K Cr 154.0% | ₹465 Cr 6.6% | ₹498 Cr 181.4% | ₹177 Cr 453.1% | ₹32 Cr 75.6% | ₹131 Cr 367.9% | ₹28 Cr 68.5% | ₹89 Cr 23.6% | ₹72 Cr |
| Investing CF | ₹-930 Cr 69.7% | ₹-548 Cr 65.6% | ₹-331 Cr 8.5% | ₹-305 Cr 29.8% | ₹-235 Cr 115.6% | ₹-109 Cr 42.6% | ₹-190 Cr 54.5% | ₹-123 Cr 18.0% | ₹-150 Cr |
| Financing CF | ₹34 Cr 53.4% | ₹73 Cr 167.6% | ₹-108 Cr 186.4% | ₹125 Cr 47.0% | ₹236 Cr 359.3% | ₹-91 Cr 139.1% | ₹233 Cr 529.7% | ₹37 Cr 43.9% | ₹66 Cr |
| Net Cash Flow | ₹285 Cr 2950.0% | ₹-10 Cr 116.9% | ₹59 Cr 1575.0% | ₹-4 Cr 112.1% | ₹33 Cr 147.1% | ₹-70 Cr 198.6% | ₹71 Cr 1675.0% | ₹4 Cr 136.4% | ₹-11 Cr |
| Free Cash Flow | ₹958 Cr 376.6% | ₹201 Cr 5.2% | ₹212 Cr 292.7% | ₹-110 Cr 50.9% | ₹-224 Cr 557.1% | ₹49 Cr 244.1% | ₹-34 Cr 0.0% | ₹-34 Cr 56.4% | ₹-78 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2016 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 67d 1.5% | 68d 6.8% | 73d 13.1% | 84d 4.5% | 88d 23.9% | 71d 19.3% | 88d 54.4% | 57d 16.2% | 68d |
| Inventory Days | 110d 7.8% | 102d 13.3% | 90d 23.1% | 117d 4.5% | 112d 20.4% | 93d 6.1% | 99d 13.9% | 115d 0.9% | 114d |
| Days Payable | 87d 9.4% | 96d 26.3% | 76d 16.5% | 91d 1.1% | 92d 24.3% | 74d 29.5% | 105d 75.0% | 60d 10.4% | 67d |
| Cash Conv. Cycle | 89d 20.3% | 74d 14.9% | 87d 21.6% | 111d 1.8% | 109d 21.1% | 90d 9.8% | 82d 26.8% | 112d 2.6% | 115d |
| Working Capital Days | 66d 7.0% | 71d 77.5% | 40d 13.0% | 46d 6.1% | 49d 25.8% | 66d 20.0% | 55d 24.7% | 73d 6.4% | 78d |
| ROCE | 15.0% 6.3% | 16.0% 700.0% | 2.0% 90.9% | 22.0% 237.5% | -16.0% 180.0% | 20.0% | — | 14.0% | — |
Source: Screener.in · Lower days = better efficiency
About Akums Drugs and Pharmaceuticals Limited
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.[1]
HealthcarePharmaceuticals & Biotechnology